Clinical Trial Update: BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma [Phase 2]

View source ↗

Summary

A Phase 2 biomarker-driven trial evaluating a VEGFR2 inhibitor in advanced or metastatic sarcoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma

Drugs mentioned

• VEGFR2 inhibitor

Snippet

Sponsor: Ruijin Hospital | Conditions: Sarcoma | Phase 2 | Status: RECRUITING